vTv Therapeutics Inc.
VTVTAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| BTIG | maintain | Buy | Oct 14, 2026 |
| HC Wainwright & Co. | maintain | Buy | Aug 6, 2026 |
| BTIG | maintain | Buy | Jul 16, 2026 |
| BTIG | maintain | Buy | Mar 11, 2026 |
| BTIG | maintain | Buy | Jan 27, 2026 |
| HC Wainwright & Co. | maintain | Buy | Dec 19, 2025 |
| HC Wainwright & Co. | maintain | Buy | Aug 13, 2025 |
| HC Wainwright & Co. | maintain | Buy | Mar 7, 2023 |
| Northland Capital Markets | maintain | Outperform | Aug 16, 2022 |
| Cantor Fitzgerald | maintain | Overweight | Feb 18, 2022 |
| HC Wainwright & Co. | maintain | Buy | Feb 10, 2020 |
| H.C. Wainwright | maintain | Buy | Feb 10, 2020 |
| HC Wainwright & Co. | maintain | Buy | May 30, 2019 |
| H.C. Wainwright | maintain | Buy | May 30, 2019 |
| Northland Capital Markets | upgrade | Market Perform →Outperform | May 5, 2019 |
| Northland Securities | downgrade | Outperform →Market Perform | Apr 10, 2018 |
| Stifel Nicolaus | downgrade | Buy →Hold | Apr 10, 2018 |
| PiperJaffray | downgrade | Overweight →Neutral | Apr 10, 2018 |
| Roth Capital | downgrade | Buy →Neutral | Apr 9, 2018 |
| Piper Sandler | downgrade | Overweight →Neutral | Apr 9, 2018 |
| Seaport Global | downgrade | Buy →Neutral | Apr 9, 2018 |
| Northland Capital Markets | downgrade | Outperform →Market Perform | Apr 9, 2018 |
| Stifel | downgrade | Buy →Hold | Apr 9, 2018 |
| Seaport Global | maintain | Buy | Mar 29, 2018 |
| Northland Securities | maintain | Outperform | Feb 8, 2018 |
Earnings History
Next report: Mar 9, 2027 · EPS est. $-1.14| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Nov 5, 2026 | $-0.94 | $-1.09 | — | $333.3K |
| Aug 6, 2026 | $-1.05 | $-0.97 | — | $333.3K |
| May 13, 2026 | $1.65 | $0.34 | $36.8M | $20.0M |
| Mar 10, 2026 | $-0.58 | $-0.98 | — | — |
| Nov 6, 2025 | $-1.08 | $-0.97 | — | — |
| Aug 12, 2025 | $-0.92 | $-0.85 | — | — |
| May 15, 2025 | $-0.77 | $-0.73 | — | — |
| Mar 20, 2025 | $-0.55 | $-0.87 | $17.0K | — |
News
Phase 2a pilot study aims to inform the design and conduct of future Phase 3 research in this population Cadisegliatin is a potential first-in-class oral therapy being evaluated as an adjunct to insulin for the treatment of T1D HIGH POINT, N.C., Oct. 27, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company advancing cadisegliatin, a novel, investigational oral therapy for type 1 diabetes (T1D), today announced that the first participant has been …
vTv Therapeutics Inc. (VTVT) Discusses Hypoglycemia Burden in Type 1 Diabetes and Cadisegliatin Phase 3 Program Transcript
vTv Therapeutics NASDAQ: VTVT used a virtual key opinion leader event to outline the continuing burden of hypoglycemia in type 1 diabetes, present patient and physician market-research findings, and review the development program for its investigational oral therapy, cadisegliatin.
Milestone supports partnering discussions for HPPD as the Company continues to prioritize its lead late-stage type 1 diabetes (T1D) program, cadisegliatin Milestone supports partnering discussions for HPPD as the Company continues to prioritize its lead late-stage type 1 diabetes (T1D) program, cadisegliatin
HIGH POINT, N.C., Oct. 06, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company advancing cadisegliatin, a novel oral investigational therapy for type 1 diabetes (T1D), today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, October 20, 2026, at 2:30 PM ET.
Jazz Pharmaceuticals (NASDAQ: JAZZ - Get Free Report) and vTv Therapeutics (NASDAQ: VTVT - Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, valuation, profitability, dividends and institutional ownership. Analyst Ratings This is a summary of current
Milestone advances Phase 3 program toward topline results expected in mid 2027 Milestone advances Phase 3 program toward topline results expected in mid 2027
vTv Therapeutics (NASDAQ: VTVT - Get Free Report) and Theravance Biopharma (NASDAQ: TBPH - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, risk, earnings, dividends, valuation, profitability and analyst recommendations. Earnings and Valuation This table compares vTv
HIGH POINT, N.C., Sept. 15, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that it granted 2,500 stock options to purchase shares of common stock to a non-executive employee as a material inducement to employment in accordance with Nasdaq Listing Rule …
HIGH POINT, N.C., Sept. 02, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company advancing cadisegliatin, a novel oral investigational therapy for type 1 diabetes (T1D), today announced that management will participate in the following investor conferences in September:
HIGH POINT, N.C., Aug. 19, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that it granted 2,500 stock options to purchase shares of common stock to a non-executive employee as a material inducement to employment in accordance with Nasdaq Listing Rule 5…